The dramatic improvements which have occurred over the past 20 years in the management of children and young people with cancer, along with the recognition of significant late effects of treatment, has led to a reappraisal of the overall philosophy of management. At a time when most children died of their disease a policy of cure 'at any cost' was justified. Now we have moved into an era of cure 'at least cost' (Morris Jones & Craft, 1990) and this is well exemplified by the management of bone tumours in young people. Indeed the 'Cade' approach to the management of osteosarcoma, namely radiotherapy to the primary tumour followed by delayed amputation if the patient had not developed metastases, could be said to be a forerunner of this philosophy in that its intention was to 'manage' at least cost.
Osteosarcoma and Ewing's tumour are the two common malignant primary bone tumours which occur in children and young adults with a peak incidence for both in the teenage years. It is at this time of life that amputation can be so devastating to a growing child with an everburgeoning perception of their own body image. Amputation in this age group is perhaps one of the most distressing forms of treatment which doctors and nurses have to inflict on patients and it is not surprising that alternative methods of therapy have been sought. Limb salvage surgery therefore has developed over the last 40 years in an attempt to mitigate the effects of this mutilating surgery. In addition to en bloc resection and replacement with a metal prosthesis other limb salvage methods have also been developed. Amongst these is rotation plasty (Kotz & Salzer, 1982) , widely used for lower femoral osteosarcoma in the remainder of Europe, but less so in the UK, which consists of resection of the tumour bone and its surrounding structure followed by rotation of the tibia through 180' and its reimplantation on the remains of the femur. The ankle then becomes the knee and the artificial limb is attached to the foot. Critics of this form of surgery suggest severe psychological distrubance may ensue but this does not seem to be the case. Many consider it a modified amputation. The primary aim of treatment for any cancer must be to cure the patient if at all possible. In the pre-chemotherapy era, only 20% of patients with osteosarcoma were cured by surgery alone and without chemotherapy or radiotherapy virtually all patients with Ewing's sarcoma died. Death was usually due to the development of distant metastases. The advent of chemotherapy has resulted in a dramatic improvement in survival for osteosarcoma patients to between 50 and 60% in most multi-institutional studies (Bramwell, 1987) . Chemotherapy and radiotherapy have led to a reported 50% survival rate for Ewing's sarcoma (Craft, 1987) . The treatment for both tumour types is in two phases, one being the definitive treatment of the primary tumour by surgery, radiotherapy or both and the other is the treatment of covert micrometastatic disease by chemotherapy. The latter usually also has some effect on the primary tumour. The definitive treatment of the primary tumour in osteogenic sarcoma must be surgery if complete ablation is to succeed, whereas this is often possible with a combination of chemotherapy and radiotherapy in Ewing's tumour. It is unlikely that, with the present chemotherapeutic agents, osteosarcoma will ever be cured without surgery. A recent report of 'flat bone' primary osteosarcoma showed that only where complete surgical excision was possible could cure be obtained (Kellie et al., 1990) . Although Ewing's tumour can be locally controlled by radiotherapy this modality does have significant late effects including radiation necrosis of bone with the risk of fracture, contraction of soft tissue with tendon shortening and the possibility of second malignancy (Tucker et al., 1977) . Because of these factors surgery has been employed more often and recently been shown to be a safe, and perhaps even a prognosticially beneficial option in the management of Ewing's tumour (Gobel et al., 1987) . Surgery should be considered mandatory in treating osteosarcoma and, although optional, may have some significant benefits in managing Ewing's tumour.
If surgery is contemplated is limb salvage with prosthetic replacement the preferred option? It is now more than 40 years since the first prosthetic replacement for a bone tumour was carried out in the UK (Seddon & Scales, 1949 ) using a hand carved 'polythene' prosthesis. Since then prostheses production and their surgical implantation has grown rapidly. Much of the knowledge of the prosthetic devices has been a consequence of the experience in arthroplasty performed for arthritic joints but the surgery itself has had to be developed specifically with cancer in mind. That the surgery can be successful is without doubt. Between 1949 and 1986 680 custom made prostheses were manufactured and inserted at the two major national bone tumour centres in the UK in London and Birmingham. Most of these were for cancer and many patients have been long term survivors with a functioning prosthesis (Kemp, 1987) .
In Europe the major group carrying out co-operative studies in Ewing's tumour is the German CESS (Cooperative Ewing's Sarcoma Study) group. In CESS 81 surgery for local control was carried out in 60 (65%) of 93 patients, 14 (15%) of these being extracompartmental resections rather than amputation (Jurgens et al., 1988) . In CESS 86 74% of patients had primary surgery, 67% of these having resection rather than amputation (H. Jurgens, personal communication). In the UK the MRC/UKCCSG have been involved in the European Osteosarcoma Intergroup (EOI) studies for osteosarcoma where there has again been an increasing use of conservative surgery from 62% in the 80831 study to 70% in 80861 (MRC unpublished data). Endoprosthetic replacement surgery therefore has gained an increasing place in the management of bone tumours in young people.
Clinicians working in this field can confidently expect some patients to walk into the room following a prosthetic replacement without any significant disability and to be leading a virtually normal life. However they also see some patients in whom there have been significant complications which may even result in eventual amputation. The media are also constantly showing us the incredible achievements of some of those who have had an amputation, because often these patients achieve more on one leg than most people achieve with two legs. Has prosthetic implant therefore been worthwhile and is it better than the alternative of amputation or for, Ewing's tumour, irradiation? It is worth assessing the major criteria on which we can judge the usefulness of this approach bearing in mind that it has been pioneered by a small group of enthusiastic surgeons.
(a) Does endoprosthetic surgery affect survival? The only way to be sure about this would be to conduct a randomised study of amputation versus prosthetic replacement between patients matched for age, sex, site and size of tumour. It is unlikely that such a surgical trial would show an improved overall survival for prosthetic replacement but it is possible that there could be differences between the groups. Local recurrence is theoretically more likely after local resection than it is following amputation. If this were so it would lead to a decrease in disease free survival of the patients receiving prosthetic implants and this could translate into lower overall survival.
Chemotherapy is undoubtedly important in the management of these high grade bone tumours. It is possible that by inserting a massive surgical procedure into the middle of a course of chemotherapy the drugs could be delayed or that other complications such as major infection, could ensue, which could compromise overall outcome. Once again this is a difficult question to answer without a randomised study. However, the influence of chemotherapy on perioperative complications in limb salvage surgery has been investigated at the Institute Rizzoli in Bologna (McDonald & Capanna, 1990) . They compared the complications in three groups of patients who had either adjuvant, neoadjuvant or no chemotherapy. Overall, infection was the most common complication occurring in 11.8% of the total of the three groups (304 patients). Taking all complications there was an incidence of 25.2% in the no chemotherapy group, 32.8% in the adjuvant and 55.4% in the neoadjuvant group. Infection led to amputation in eight of the most severely affected of the 36 patients who had this complication. This study seems to suggest that chemotherapy does increase the incidence of complications in limb salvage surgery, but we do not know if this resulted in a significant change to the chemotherapy regimen or to the ultimate survival of the patients.
It is much more difficult to comply with the requirements of good cancer surgery with en bloc resection than it is with an amputation. Inadvertent tumour contamination of the wound is a greater possibility in en bloc resection. The significance of this was studied by Enneking (Enneking & Maale, 1988) . They found the incidence of local recurrence in known wound contamination was substantial and that this could be best influenced by immediate re-excision. Adjuvant chemotherapy was of less benefit in preventing local recurrence.
Attempts have been made to compare survival in apparently similar patients treated by either amputation or limb salvage surgery. Simon and colleagues collected data from a number of institutions in the United States and could detect no difference in survival according to type of surgery (Simon et al., 1986) . Even in patients treated on a common protocol in the US CCSG studies, no difference in survival was seen with the different types of surgery (Makley & Krailo, 1988) . However the results of a multi-institutional study in Japan (Tomita & Tsuchiya, 1989) and in Europe (Jurgens et al., 1988) following surgery the number of patients rated 'excellent' or 'good' was high but the number rated as 'fair' or 'poor' increased after a 4 year follow up mainly due to post surgical complications (Tomita & Tsuchiya, 1989) . Van der Eyken (personal communication) carried out a study 'in the field' of emotional adjustment and functional ability in a group of 36 adolescents who had either endoprosthetic replacement, amputation or rotationplasty and who were taking part in a skiing holiday. There is no doubt that the best adjusted and functionally most active were those who had rotationplasty. However once again these patients were selected for their particular surgical procedure and it may well be that only the emotionally stable were offered rotationplasty. Sugarbaker et al. (1982) studied the quality of life in patients with soft tissue sarcomas treated by either amputation or limb sparing surgery and was unable to show any difference in the two gruops using well validated rating scales. Indeed the only significant findings in the study were that, when compared with limb salvage patients, amputees were both better emotionally adjusted and had superior 'body care and movement' as well as having better scores for 'health care orientation' and 'sexular relationships'. A similar result was also found by Weddington et al. (1985) . An additional approach which can be studied when assessing functional outcome is to measure the energy cost of gait. Otis and colleagues in New York (Otis et al., 1985) (Lewis, 1986) there is the additional problem of repeated minor surgical procedures every 3 months in order to lengthen the prosthesis. Most endoprostheses are put into young active people who wish to lead a normal life and many of these are likely to live a normal life span. The life span of endoprosthetic devices is not known, but by extrapolation from similar devices put into older, more sedentary people, it is likely that many will require further revision surgery in 10 to 20 years.
(d) What are the relative costs? Amputation only requires a few days in hospital and up to 2 h of theatre time. However there is the cost of providing an external prosthetic device with replacement for the rest of a patients life. Endoprosthetic replacement on the other hand requires much longer in hospital, the cost of the device, up to £1500, and there are several hours of theatre time. In addition the costs of hospitalisation for surgical complications and revision surgery have to be taken into account. It is likely therefore that endoprosthetic surgery will prove more expensive over a lifetime.
(e) Other factors to be considered At present custom made endoprosthetic surgery in the UK has been developed at two major centres i.e. Birmingham and London both of whom have recently received supraregional funding for the service which they provide. Decentralisation of this service has up until now been discouraged because of the difficulties of providing custom made prostheses and the need to concentrate and develop expertise. Because of the considerable problems of travel and accomodation for patients and their families from distant parts of the UK and possible disruption of chemotherapy and continuing care, other major regional centres have recently started to carry out such procedures and are gaining the necessary expertise to be able to provide an adequate service. However there are as yet no recommendations as to the training required for surgeons undertaking this type of procedure, to the facilities and backup needed nor to the minimum number of patients necessary to maintain expertise of all relevant disciplines within a centre. Perhaps this is something which the British Orthopaedic Association could address in association with other disciplines. One of the major limiting factors in the past has been the supply of custom made prostheses which, in the UK have been manufactured at Stanmore and only been made available to the two major centres. Many prosthetic devices are now commercially available and the modular system designed by Kotz (Kotz & Engel, 1983) gives the flexibility to 'design' the prosthesis at the time of surgery in contrast to the complex preoperative assessment and delay in manufacture of custom made devices.
Conspectus
Endoprosthetic surgery probably does not influence overall survival. It is likely to be more expensive over a lifetime and although it may produce better cosmetic results it may not have any real functional advantage.
Endoprosthetic surgery for bone cancer is well established and where available is likely to remain a favoured operation. It is highly unlikely that agreement could ever be reached to undertake a randomised study of endoprosthesis versus amputation. Even if the doctors concerned could reach a consensus it is likely that there would be very considerable difficulties with patient randomisation. The best that can be done is to prospectively collect and assess relevant surgical and outcome data in the major therapeutic studies which are now underway or are planned throughout the world. If a simple, standardised form of functional assessment could be devised and applied across studies then perhaps in the future we would be able to discuss what really is best for this important group of young active patients who now have a good chance of being cured of their cancer. In the meantime, we can offer endoprosthetic surgery where it is available, but in the present state of knowledge there is nothing to suggest that patients who have an amputation are receiving inferior treatment.
